[go: up one dir, main page]

NO20035571L - N-formyl hydroksylaminforbindelser som PDF-inhibitorer - Google Patents

N-formyl hydroksylaminforbindelser som PDF-inhibitorer

Info

Publication number
NO20035571L
NO20035571L NO20035571A NO20035571A NO20035571L NO 20035571 L NO20035571 L NO 20035571L NO 20035571 A NO20035571 A NO 20035571A NO 20035571 A NO20035571 A NO 20035571A NO 20035571 L NO20035571 L NO 20035571L
Authority
NO
Norway
Prior art keywords
hydroxylamine compounds
treatment
formyl hydroxylamine
pdf inhibitors
inhibitors
Prior art date
Application number
NO20035571A
Other languages
English (en)
Other versions
NO20035571D0 (no
NO327420B1 (no
Inventor
Dinesh V Patel
Zhengyu Yuan
Rakesh K Jain
Salvador Garcia Alvarez
Jeffrey Jacobs
Original Assignee
Vicuron Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicuron Pharm Inc filed Critical Vicuron Pharm Inc
Publication of NO20035571D0 publication Critical patent/NO20035571D0/no
Publication of NO20035571L publication Critical patent/NO20035571L/no
Publication of NO327420B1 publication Critical patent/NO327420B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

N- [ 1 -okso-2-alkyl-3 -(N-hydroksy formamido)-propyl]-(karbonylamino-aryl eller -heteroaryl)-azacyklo_alkaner eller tiazacyklo_alkaner eller imidazacyklo.alkaner har interessante egenskaper, for eksempel ved behandling eller hindring av forstyrrelser som kan påvirkes av behandling av peptidyldeformylaseinhibitorer slike som behandling av bakterieinfeksjoner.
NO20035571A 2001-06-15 2003-12-12 N-formylhydroksylaminforbindelser, fremgangsmate til fremstilling derav, farmasoytiske sammensetninger og celledyrkningsmedium inneholdende slike forbindelser, samt anvendelse derav som legemiddel. NO327420B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29841901P 2001-06-15 2001-06-15
US36031302P 2002-02-27 2002-02-27
PCT/EP2002/006604 WO2002102790A1 (en) 2001-06-15 2002-06-14 N-formyl hydroxylamine compounds as inhibitors of pdf

Publications (3)

Publication Number Publication Date
NO20035571D0 NO20035571D0 (no) 2003-12-12
NO20035571L true NO20035571L (no) 2004-02-16
NO327420B1 NO327420B1 (no) 2009-06-29

Family

ID=26970649

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035571A NO327420B1 (no) 2001-06-15 2003-12-12 N-formylhydroksylaminforbindelser, fremgangsmate til fremstilling derav, farmasoytiske sammensetninger og celledyrkningsmedium inneholdende slike forbindelser, samt anvendelse derav som legemiddel.

Country Status (30)

Country Link
US (1) US7148242B2 (no)
EP (1) EP1401828B1 (no)
JP (1) JP4361365B2 (no)
KR (2) KR100589544B1 (no)
CN (1) CN1511152A (no)
AR (1) AR036053A1 (no)
AT (1) ATE323081T1 (no)
AU (1) AU2002321062B2 (no)
BR (1) BR0210377A (no)
CA (1) CA2448526A1 (no)
CO (1) CO5640131A2 (no)
CY (1) CY1105085T1 (no)
CZ (1) CZ20033388A3 (no)
DE (1) DE60210612T2 (no)
DK (1) DK1401828T3 (no)
ES (1) ES2262824T3 (no)
HU (1) HUP0400208A3 (no)
IL (1) IL158770A0 (no)
MX (1) MXPA03011628A (no)
MY (1) MY138619A (no)
NO (1) NO327420B1 (no)
NZ (1) NZ529489A (no)
PE (1) PE20030100A1 (no)
PL (1) PL364476A1 (no)
PT (1) PT1401828E (no)
RU (1) RU2325386C2 (no)
SI (1) SI1401828T1 (no)
SK (1) SK15242003A3 (no)
WO (1) WO2002102790A1 (no)
ZA (1) ZA200308379B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60219630T2 (de) * 2001-06-15 2007-12-27 Vicuron Pharmaceuticals, Inc., Fremont Bicyclische pyrrolidinverbindungen
GB0208579D0 (en) * 2002-04-13 2002-05-22 British Biotech Pharm Antibacterial agents
ES2321504T3 (es) * 2002-09-19 2009-06-08 Novartis Ag Proceso para la preparacion de productos intermedios.
CA2516465A1 (en) 2003-02-21 2004-09-10 Novartis Ag Chemical process for the preparation of intermediates to obtain n-formyl hydroxylamine compounds
TW200427458A (en) * 2003-04-02 2004-12-16 Novartis Ag Crystalline N-formyl hydroxylamine compounds
BRPI0411921A (pt) * 2003-06-26 2006-08-15 Novartis Ag processo para preparar intermediários úteis para preparar determinadas hidroxilaminas de n-formila antibacterianas
KR100527624B1 (ko) * 2003-08-21 2005-11-22 한기종 질소에 포밀기를 갖는 아민유도체의 새로운 제조방법
WO2006002896A1 (en) * 2004-06-30 2006-01-12 Novartis Ag Method for increasing the susceptibility of peptide deformylase inhibitors by using efflux pump inhibitors
WO2006055663A2 (en) 2004-11-17 2006-05-26 Smithkline Beecham Corporation The use of novel antibacterial compounds
GT200600196A (es) * 2005-05-23 2007-01-15 Compuestos n-formil de hidroxilamina
DE102005026231A1 (de) * 2005-06-07 2006-12-14 Origenis Ag Peptid-Deformylase (PDF) Inhibitoren 3
EP1893574A2 (en) * 2005-06-07 2008-03-05 Novartis AG Peptide deformylase (pdf) inhibitors 4
SG133452A1 (en) * 2005-12-30 2007-07-30 Novartis Ag Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases
CA2643267A1 (en) * 2006-03-03 2007-09-20 Novartis Ag N-formyl hydroxylamine compounds
CN101328155B (zh) * 2007-06-20 2010-11-03 上海医药工业研究院 噁唑烷衍生物及其制备方法和应用
CN101434570B (zh) * 2007-11-16 2011-02-02 上海医药工业研究院 吡咯烷衍生物及其制备方法和应用
CN101584694B (zh) * 2009-06-15 2011-01-12 华东师范大学 含2,5-二氢吡咯的肽脱甲酰基酶抑制剂及合成方法
EP2473502A1 (en) * 2009-09-04 2012-07-11 Novartis AG Heteroaryl compounds as kinase inhibitors
NZ627520A (en) * 2010-03-10 2015-10-30 Astrazeneca Ab 4-phenyl pyridine analogues as protein kinase inhibitors
JP5825086B2 (ja) 2011-12-19 2015-12-02 住友化学株式会社 α−置換−β−アミノ酸エステル誘導体不斉加水分解酵素
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
ES2876974T3 (es) 2015-04-07 2021-11-15 Novartis Ag Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
US10738028B2 (en) * 2016-05-11 2020-08-11 Rudong Ruien Pharmaceutical Technology Co. Ltd Spiro three-membered ring, spiro five-membered ring peptide deformylase inhibitor and use thereof in antibacteria and anti-tumor

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3206411A (en) * 1963-10-11 1965-09-14 American Cyanamid Co Novel substituted 3-formyl-and 3-lower alkanoyl-4,5-indoloquinones and novel methodsof preparing the same
US4052511A (en) 1976-02-13 1977-10-04 E. R. Squibb & Sons, Inc. Carboxyacylproline derivatives
US4311705A (en) 1980-10-06 1982-01-19 E. R. Squibb & Sons, Inc. Carboxyalkanoyl and hydroxycarbamoylalkanoyl derivatives of substituted prolines
US4303662A (en) 1980-11-24 1981-12-01 E. R. Squibb & Sons, Inc. Carboxyacyl, mercapto and acylmercapto derivatives of heterobicyclo compounds
US4321383A (en) 1980-11-24 1982-03-23 E. R. Squibb & Sons, Inc. Heterobicyclo intermediates
JPS6188884A (ja) 1984-10-04 1986-05-07 Sankyo Co Ltd エンケフアリナ−ゼb阻害物質およびその製法
AU580855B2 (en) * 1985-03-29 1989-02-02 Shionogi & Co., Ltd. Alkeneamidocephalosporin esters
US4599361A (en) 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
DK77487A (da) 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
FR2609289B1 (fr) 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
US5128346A (en) 1987-09-21 1992-07-07 Abbott Laboratories Derivatives of D-glutamic acid and D-aspartic acid
EP0334244A3 (en) 1988-03-25 1991-05-29 The Procter & Gamble Company Bradykinin antagonist peptides
GB8827308D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8919251D0 (en) 1989-08-24 1989-10-04 British Bio Technology Compounds
GB8921326D0 (en) 1989-09-21 1989-11-08 Beecham Group Plc Novel treatment
US5268384A (en) 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
JPH05503720A (ja) 1990-12-03 1993-06-17 セルテック リミテッド ペプチジル誘導体
CA2058797A1 (en) 1991-02-01 1992-08-02 Michael John Broadhurst Amino acid derivatives
GB9102635D0 (en) 1991-02-07 1991-03-27 British Bio Technology Compounds
IT1245712B (it) 1991-04-09 1994-10-14 Boehringer Mannheim Italia Ammine eterocicliche utili terapia dell'asma e dell'infiammazione delle vie aeree
WO1992022523A2 (en) 1991-06-14 1992-12-23 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
US5256657A (en) 1991-08-19 1993-10-26 Sterling Winthrop, Inc. Succinamide derivative matrix-metalloprotease inhibitors
JPH05125029A (ja) 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
ES2145014T3 (es) 1991-11-08 2000-07-01 Sankyo Co Derivados de piperazina como inhibidores de la colagenasa.
JP3348725B2 (ja) 1992-04-07 2002-11-20 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド ヒドロキサム酸ベースのコラゲナーゼとサイトカイン阻害剤
GB9211706D0 (en) 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
GB9211707D0 (en) 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5318964A (en) 1992-06-11 1994-06-07 Hoffmann-La Roche Inc. Hydroxamic derivatives and pharmaceutical compositions
GB9215665D0 (en) 1992-07-23 1992-09-09 British Bio Technology Compounds
US5552419A (en) 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
WO1994021612A1 (en) 1993-03-18 1994-09-29 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives as matrix metalloproteinases inhibitors
ATE182137T1 (de) 1993-04-27 1999-07-15 Celltech Therapeutics Ltd Peptidylderivate als inhibitoren von metalloproteinase
GB9308695D0 (en) 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
GB9501737D0 (en) 1994-04-25 1995-03-22 Hoffmann La Roche Hydroxamic acid derivatives
GB9411598D0 (en) 1994-06-09 1994-08-03 Hoffmann La Roche Hydroxamic acid derivatives
GB9502858D0 (en) 1995-02-14 1995-04-05 British Biotech Pharm Novel use of matrix metalloproteinase inhibitors
GB9504084D0 (en) 1995-03-01 1995-04-19 British Biotech Pharm Synthesis of carboxylic and hydroxamic acid derivatives
FR2733750B1 (fr) 1995-05-03 1997-06-13 Synthelabo Derives de l'acide gamma-oxo-alpha-(phenylmethyl)-5,6- dihydro-4h-thieno(3,4-c)pyrrole-5-butanoique, leur preparation et leur application en therapeutique
ES2248840T3 (es) 1996-02-23 2006-03-16 Eli Lilly And Company Antagonistas de vasopresina v1a no peptidilicos.
TW448172B (en) 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
GB9613547D0 (en) 1996-06-27 1996-08-28 Pharmacia Spa Matrix metalloproteinase inhibitors
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
WO1999002510A1 (en) 1997-07-10 1999-01-21 Pharmacia & Upjohn S.P.A. Matrix metalloproteinase inhibitors
EP1052984B1 (en) * 1998-02-07 2004-05-12 Vernalis (Oxford) Ltd Antibacterial agents

Also Published As

Publication number Publication date
RU2325386C2 (ru) 2008-05-27
CA2448526A1 (en) 2002-12-27
SK15242003A3 (sk) 2004-07-07
AU2002321062B2 (en) 2006-02-02
US7148242B2 (en) 2006-12-12
DE60210612T2 (de) 2006-09-21
PT1401828E (pt) 2006-08-31
BR0210377A (pt) 2004-08-10
NO20035571D0 (no) 2003-12-12
CN1511152A (zh) 2004-07-07
HUP0400208A2 (hu) 2004-06-28
RU2003137565A (ru) 2005-05-27
MY138619A (en) 2009-07-31
ES2262824T3 (es) 2006-12-01
ZA200308379B (en) 2004-05-21
CY1105085T1 (el) 2009-11-04
WO2002102790A1 (en) 2002-12-27
PL364476A1 (en) 2004-12-13
EP1401828B1 (en) 2006-04-12
IL158770A0 (en) 2004-05-12
EP1401828A1 (en) 2004-03-31
JP4361365B2 (ja) 2009-11-11
PE20030100A1 (es) 2003-03-28
NZ529489A (en) 2005-10-28
HUP0400208A3 (en) 2008-10-28
KR20060014083A (ko) 2006-02-14
KR20040010721A (ko) 2004-01-31
DE60210612D1 (de) 2006-05-24
KR100589544B1 (ko) 2006-06-15
CO5640131A2 (es) 2006-05-31
NO327420B1 (no) 2009-06-29
CZ20033388A3 (en) 2004-03-17
DK1401828T3 (da) 2006-07-31
HK1064370A1 (en) 2005-01-28
ATE323081T1 (de) 2006-04-15
SI1401828T1 (sl) 2006-10-31
MXPA03011628A (es) 2005-03-07
AR036053A1 (es) 2004-08-04
JP2005502606A (ja) 2005-01-27
US20030045479A1 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
NO20035571L (no) N-formyl hydroksylaminforbindelser som PDF-inhibitorer
EP3569601A3 (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
NO20061479L (no) Anvendelse av modifiserte cyklosporiner for behandling av HCV-forstyrrelser
NO20075815L (no) Formuleringer og metoder for behandling av amyloidose
NO20071549L (no) Nye benzofuserte heteroalrylsulfamidderivater, anvendelige som anti-krampemidler
WO2004056315A8 (en) Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
BRPI0416268A (pt) composições de delta-9-thc e métodos para o tratamento de sintomas associados à esclerose múltipla
WO2002007742A3 (en) Bacteriophage having multiple host range
TR200102969T2 (tr) Siklik protein tirozin kinaz önleyicileri.
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
DE60022692D1 (de) (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
NO20085373L (no) P38 inhibitorer, deres fremstilling og anvendelse
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
NO20054359L (no) Cykliske protein tyrosin kinase inhibitorer
NO20084912L (no) Bisykliske derivater som CETP-inhibitorer
NO20003233L (no) 4-hydroksykinolin-3-karboksamider og hydrazider som antivirale midler
WO2005118511A3 (en) Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2003026567A3 (en) Use of neuraminidase inhibitors to prevent flu associated bacterial infections
ATE427116T1 (de) Behandlung von bakteriellen infektionen
WO2004052858A3 (en) Inhibitors of monoamine uptake
NO20053348D0 (no) Farmasoytisk sammensetning for behandling av virusangrep.
WO2003072537A3 (en) Selective protein tyrosine phosphatatase inhibitors
BRPI0410967A (pt) compostos, composições e seus usos para o tratamento de infecções por vìrus da famìlia flaviviridae
WO2005011611A3 (en) Bicyclic compounds and compositions as pdf inhibitors
ATE338542T1 (de) Verwendung trifluoracetylalkyl-substituierter phenyl-, phenol- und benzoylderivate in der behandlung und/oder prophylaxe von obesitas und deren begleit- und/oder folgeerkrankungen

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees